Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342456 | 0.90 | IKBKB (0.60) | IKBKBCHUK | |
| SCHEMBL5340714 | 0.89 | IKBKB (0.73) | IKBKBCHUK | |
| SCHEMBL5334616 | 0.88 | IKBKB (0.69) | IKBKBCHUK | |
| SCHEMBL5340373 | 0.87 | IKBKB (0.72) | IKBKBCHUK | |
| SCHEMBL5337426 | 0.87 | IKBKB (0.80) | IKBKBCHUK | |
| SCHEMBL5375444 | 0.87 | IKBKB (0.81) | IKBKBCHUK | |
| SCHEMBL5334146 | 0.86 | IKBKB (0.67) | IKBKBCHUK | |
| SCHEMBL5334407 | 0.85 | IKBKB (0.72) | IKBKBCHUK | |
| SCHEMBL5336397 | 0.85 | IKBKB (0.78) | IKBKBCHUK | |
| SCHEMBL5338033 | 0.84 | IKBKB (0.73) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | claimed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | claimed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | claimed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7161018-B2 | Soluble late transition metal catalysts for olefin oligomerizations II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040039238-A1 | Soluble late transition metal catalysts for olefin oligomerizations II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039238-A1 | Soluble late transition metal catalysts for olefin oligomerizations II | OCIAD2, ORAI2, SPINT2 | IKBKB 1869/4885CHUK 1581/4885 |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | IKBKB 55/4885CHUK 32/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | IKBKB 55/4885CHUK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.